{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:03Z","timestamp":1761871203234,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.clml.2018.06.013","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T05:11:43Z","timestamp":1529039503000},"page":"664-672.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1788-4944","authenticated-orcid":false,"given":"Leslie","family":"Padrnos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-1085","authenticated-orcid":false,"given":"Amylou C.","family":"Dueck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi E.","family":"Kosiorek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda F.","family":"Ginos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Toro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose F.","family":"Leis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Colgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Porrata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.06.013_bib2","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.013_bib3","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.013_bib4","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-Cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib5","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib6","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood.V124.21.628.628","article-title":"A\u00a0phase 2\/3 multicenter, randomized study comparing the efficacy and safety of lenalidomide versus investigator's choice in relapsed\/refractory DLBCL","volume":"124","author":"Czuczman","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.013_bib7","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.06.013_bib9","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib10","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O'Donnell","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib11","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.06.013_bib12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","article-title":"A\u00a0phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma","volume":"85","author":"Johnston","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.06.013_bib13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ajh.24671","article-title":"Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma","volume":"92","author":"Bennani","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.06.013_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A\u00a0phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.06.013_bib15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.23620","article-title":"Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia","volume":"89","author":"Ghobrial","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.06.013_bib16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2015-02-629543","article-title":"The mTORC1 inhibitor everolimus has antitumor activity in\u00a0vitro and produces tumor responses in patients with relapsed T-cell lymphoma","volume":"126","author":"Witzig","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.013_bib17","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s10637-013-0013-1","article-title":"Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer","volume":"31","author":"Ganesan","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2018.06.013_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bjh.12909","article-title":"Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide","volume":"166","author":"Yee","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.06.013_bib19","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib20","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib21","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.013_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trnen\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib23","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A Phase 2\/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.06.013_bib24","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.2009.24.0994","article-title":"Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib25","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.06.013_bib26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.12845","article-title":"Clinical activity of everolimus in relapsed\/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group","volume":"166","author":"Conconi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.06.013_bib27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bjhh.2017.03.008","article-title":"Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience","volume":"39","author":"Rocha","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.clml.2018.06.013_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-018-0103-z","article-title":"Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma","volume":"7","author":"Johnston","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib29","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.hoc.2007.06.011","article-title":"The International Harmonization Project for response criteria in lymphoma clinical trials","volume":"21","author":"Cheson","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2018.06.013_bib30","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.013_bib31","unstructured":"Revlimid Prescribing Information, Celgene. Available at: http:\/\/media.celgene.com\/content\/uploads\/revlimid-pi.pdf. Accessed January 4, 2018."},{"key":"10.1016\/j.clml.2018.06.013_bib32","doi-asserted-by":"crossref","first-page":"6882","DOI":"10.1158\/1078-0432.CCR-13-1906","article-title":"Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma","volume":"19","author":"Oki","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.06.013_bib33","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/annonc\/mdv624","article-title":"A\u00a0phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib34","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(16)30040-0","article-title":"Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial","volume":"3","author":"Johnston","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2018.06.013_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib36","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.06.013_bib37","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/blood-2016-06-718106","article-title":"Phase I study of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance 051103l","volume":"128","author":"Ujjani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.013_bib38","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V124.21.3091.3091","article-title":"Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed\/refractory B cell lymphomas: Alliance A051201 and A051202","volume":"124","author":"Smith","year":"2014","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018303355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018303355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:48Z","timestamp":1761870708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018303355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S2152265018303355"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.06.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}